Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
76
resultados
Última actualización
16/10/2026 [07:43:00]
Resultados 25 a 50 de 76
Resumen de: CN122466087A
The invention discloses an application of miR-122b-3p (micro Ribonucleic Acid-122b-3p) in cardiovascular calcification. It is found for the first time that inhibition of miR-122b-3p can reduce calcium deposition and calcium content of cardiovascular smooth muscle cells, and it is found that sodium thiosulfate can treat coronary artery calcification of MHD patients by reducing the miR-122b-3p level. On the basis, the invention provides application of a reagent for detecting the miR-122b-3p level in preparation of a product for evaluating the curative effect of sodium thiosulfate on cardiovascular calcification of an MHD patient and application of a miR-122b-3p inhibitor in preparation of a medicine for treating cardiovascular calcification. Meanwhile, the invention also provides an extracellular vesicle generated by the cell transfected with the miR-122b-3p inhibitor, the extracellular vesicle can also significantly reduce calcium deposition and calcium content of cardiovascular smooth muscle cells, and these results show that miR-122b-3p plays an important role in coronary artery calcification and has a wide clinical application prospect.
Resumen de: CN122465915A
The invention relates to an application of shLepr-based adeno-associated virus in preparation of a medicine for treating heart failure. The invention discloses a gene therapy for treating heart failure based on an AAV-shLepr adeno-associated virus vector. According to the present invention, the deficiency of the whole genome Adtrp results in heart dysfunction and heart failure, the deficiency of the Adtrp further aggravates the heart dysfunction and the heart failure, the results show that the deficiency of the Adtrp results in the heart failure, the AAV-shLepr gene therapy can effectively block the heart failure development of CAD and TAC models, the expression levels of Lepr, Apob, Col7a1, adhesion molecules Icam-1, Vcam-1, E-selectin, P-selectin and p65 are changed, and the AAV-shLepr gene therapy can reverse the effect; lepR plays an important role in the pathogenesis of heart failure, and by using AAV-shLepr gene therapy, heart dysfunction and heart failure of CAD and TAC model heart failure can be remarkably relieved. The research provides a new treatment strategy for the treatment of heart failure.
Resumen de: CN122465936A
The embodiment of the invention discloses an MYH6 gene variant and application thereof, and belongs to the technical field of biology. Compared with a wild type MYH6 gene, the MYH6 gene variant has c.1432Tgt in a No.14 exon region, c.1432Tgt in a No.6 exon region, and c.1432Tgt in a No.6 exon region. G, heterozygous missense variation. According to the invention, the c.1432Tgt of the MYH6 gene is found for the first time; according to the present invention, the G heterozygous missense variation is the possible pathogenic variation of the hypertrophic cardiomyopathy, the discovery enriches the pathogenic variation spectrum of the hypertrophic cardiomyopathy, the brand new biomarker is provided for the early diagnosis of the hypertrophic cardiomyopathy, and the biomarker can effectively assist the clinical development of the related diagnosis work of the hypertrophic cardiomyopathy, and can provide the clinical application of the hypertrophic cardiomyopathy in the clinical treatment of the hypertrophic cardiomyopathy. The invention has important clinical application value and social significance.
Resumen de: CN122445787A
The invention relates to the technical field of molecular biology, and discloses a DNA methylation marker and application thereof in an acute ischemic stroke diagnostic kit, and the DNA methylation marker comprises methylation regions of genes of CDH2, PCDHB10, PCDHB11, PCDHB14, PCDHB16, PCDHB3 and PCDHB9. According to the invention, 12 methylation region combinations of 7 marker genes with high specificity and high sensitivity, which are highly related to the early attack risk of acute ischemic stroke, are screened and obtained, and when the combination of methylation regions is used as a marker for early detection of acute ischemic stroke, the result accuracy is high; and auxiliary diagnosis reference can be provided for clinicians.
Resumen de: CN122440657A
The invention discloses an application of piRNA-AMIPIR (piRNA-AMIPIR) in preparation of a medicine for improving heart injury after acute myocardial infarction. According to the invention, high expression of piRNA-AMIPIR in myocardial tissue after acute myocardial infarction (MI) is found for the first time, and the expression level of piRNA-AMIPIR is in positive correlation with myocardial injury degree. After the antisense nucleotide Antagomir-AMIPIR designed on the basis of the piRNA-AMIPIR is administered in a mouse acute myocardial infarction model, inflammatory cell infiltration can be inhibited by reducing myocardial cell apoptosis and reactive oxygen species (ROS) accumulation, the systolic function of the heart can be remarkably improved, and ischemia-induced heart injury can be relieved. According to the application, the potential value of piRNA-AMIPIR serving as a cardiac injury treatment target spot after acute myocardial infarction is defined, the antisense nucleotide of piRNA-AMIPIR provides a new candidate drug and a treatment strategy for clinical treatment of acute myocardial infarction, and important scientific research significance and clinical application prospects are achieved.
Resumen de: US20260210975A1
0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.
Resumen de: US20260209290A1
Disclosed is a method, a pharmaceutical composition, and a pharmaceutical preparation for prevention and/or treatment of pulmonary arterial hypertension (PAH). The method includes administering to a subject at least one of a first agent that inhibits binding of Hic-5 to SMAD7 or a second agent that inhibits Hic-5.
Resumen de: WO2026156121A1
The present disclosure relates generally to the treatment of subjects having a lipid disorder or a cardiovascular disease or at risk of developing a lipid disorder or a cardiovascular disease by administering a Phospholipase A2 Group XIIB (PLA2G12B) inhibitor to the subject.
Resumen de: US20260207775A1
The invention relates to the field of diseases caused by high levels of LDL-C and/or fibrinogen, such as cardiovascular disease. The invention involves oligonucleotides for RNA editing technology in deaminating target adenosine nucleotides, such as the adenosine at position 1055, in transcripts of the human B4GALT1 gene.
Resumen de: CN122424338A
The invention relates to application of SIRT5 as an abdominal aortic aneurysm treatment target, and relates to the technical field of biological medicine. It is confirmed for the first time that expression of SIRT5 in human abdominal aortic aneurysm tissues, animal models and pathological stimulated vascular smooth muscle cells is significantly up-regulated and is closely related to phenotypic transformation of the vascular smooth muscle cells, occurrence and development of AAA can be significantly inhibited by specifically knocking out SIRT5 from the vascular smooth muscle cells, and the pathological process of AAA is aggravated by overexpression of SIRT5, so that the AAA can be effectively inhibited. The SIRT5 can be used as an intervention target of AAA, and in an animal model, it is proved that MC3482 can significantly inhibit formation of abdominal aortic aneurysm, a brand-new drug intervention target and a candidate compound are provided for abdominal aortic aneurysm, and a solid foundation is laid for treatment of abdominal aortic aneurysm and subsequent drug development.
Resumen de: CN122428033A
The invention relates to the field of biological medicine, and discloses application of TARS2 in preparation of cardiac injury diagnosis products and therapeutic drugs. The invention provides a molecular index capable of diagnosing chemotherapy drug induced cardiac mitochondrial oxidative stress and myocardial injury, and the molecular index can be targeted to prevent or treat cardiotoxicity and improve the life quality of tumor chemotherapy patients.
Resumen de: CN122399027A
The invention provides application of an ATP6v0a1 regulating agent in preparation of a medicine for preventing and/or relieving and/or treating dilated cardiomyopathy and/or heart failure. The application provided by the invention provides a brand new molecular target for the treatment of DCM and heart failure; furthermore, the ATP6v0a1 regulating agent provided by the invention can be used for effectively treating dilated cardiomyopathy and heart failure, and has better treatment potential and specificity compared with a traditional symptomatic treatment medicine.
Resumen de: CN122405814A
The invention provides a biomarker RAB10 for diagnosing collateral circulation establishment and application of the biomarker RAB10, and belongs to the technical field of biomedicine. The new application of the RAB10 in the cardiovascular treatment field is found for the first time, the cognition that the existing research of the RAB10 is only limited to the tumor field is broken through, and the RAB10 is creatively applied to the brand new treatment scene of coronary artery collateral circulation establishment. A rigorous cell experiment proves that the proliferation, migration and angiogenesis of endothelial cells can be obviously promoted by the overexpression of the RAB10, which directly proves that the positive regulation and control effect of the RAB10 in angiogenesis and provides a direct experimental basis for the application of the RAB10 in therapeutic angiogenesis. The invention further provides that the RAB10 can be used as a biological marker for evaluating the collateral circulation establishment potential of the CTO patient, a new tool is provided for predicting the long-term prognosis of the patient and formulating an individualized treatment strategy, and the RAB10 has an important clinical transformation prospect.
Resumen de: WO2026149323A1
Provided are the methods of use and pharmaceutical compositions of mitochondrial uncouplers and glucagon-like peptide-1 receptor agonists for treating various diseases and conditions, including obesity, T2DM, liver diseases and conditions (e.g., MASH), and cardiovascular diseases and conditions(e.g.,heart failure).
Resumen de: WO2026152007A1
Disclosed are methods for assessing the likelihood of a subject developing coronary artery disease (CAD). The methods comprise determining a polygenic risk score based on a set of single nucleotide polymorphisms associated with endothelial cell function. The assessment may include the subject's LDL-C levels as a factor, and the methods include determining a subject's sensitivity to LDL-C mediated CAD. Determination of increased risk for CAD is followed by treatment with an anti-CAD therapy.
Resumen de: US20260201372A1
0000 Compositions and methods are disclosed for treating metabolic syndrome-associated heart disease cardiomyopathy and/or heart failure, wherein the method comprises the step of increasing the concentration of LIPTER RNA in the cardiomyocytes of said patient.
Resumen de: US20260201474A1
0000 The present disclosure relates generally to methods for accurately predicting the risk of cancer-associated venous thromboembolism (CAT) and/or preventing CAT in cancer patients using ctDNA as a biomarker.
Resumen de: WO2026148565A1
The use of annexin A2 (ANXA2) and an inhibitor thereof in the diagnosis, treatment and/or prevention of pulmonary hypertension. Specifically disclosed is the use of an ANXA2 inhibitor (comprising an siRNA for silencing the ANXA2 gene, an ANXA2 antibody, and a phosphorylation inhibitor) in the preparation of a product for preventing and/or treating pulmonary hypertension. It is verified in experiments that the ANXA2 inhibitor can significantly inhibit the proliferation and migration of pulmonary arterial smooth muscle cells, and significantly ameliorate pulmonary hypertension, pulmonary arterial vascular remodeling, and right ventricular hypertrophy. The ANXA2 or ANXA2 protein Thr208 phosphorylation site can be used in the diagnosis or assisted diagnosis of pulmonary hypertension, or in the screening of drugs for pulmonary hypertension and the development of new diagnostic and therapeutic methods and drugs. The developed therapeutic target and ANXA2 inhibitor have a high clinical application value in the fields of diagnosis, prevention, and treatment of pulmonary hypertension.
Resumen de: CN122376742A
The invention relates to the technical field of biological medicines, and discloses medical application of HSPD1 acetylation modification in prevention or treatment of myocardial infarction. The invention discovers that the acetylation level of the K352 site of the HSPD1 protein is specifically up-regulated in the pathological process of myocardial infarction for the first time, the cardiac function after myocardial infarction can be remarkably improved by up-regulating the acetylation level of the site, and myocardial fibrosis and myocardial cell hypertrophy are inhibited; when the acetylation level of the site is reduced, myocardial ischemia injury can be aggravated, and the cardiac function can be deteriorated. According to the invention, HSPD1 K352 site acetylation can be used as a new target for prevention, treatment and auxiliary diagnosis of myocardial infarction, and a theoretical basis and an experimental basis are provided for research and development of myocardial infarction targeted drugs and gene therapy products.
Resumen de: CN122382188A
The invention provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosis or auxiliary diagnosis of fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. According to the invention, miRNA microarray analysis is adopted to analyze the expression characteristics of the serum exosome microRNA in pregnancy affected by CHD compared with a matched healthy control. In the early pregnancy period and the late pregnancy period of TOF fetal pregnancy, the miR-1909-3p is remarkably overexpressed in maternal circulation, which indicates that the miR-1909-3p is a potential biomarker of the fetal congenital heart disease. Through verification set ROC curve analysis, it is found that the area under a curve is 0.953, Plt; the result shows that the miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening, the sensitivity is 95%, and the specificity is 95%.
Resumen de: CN122351311A
The invention relates to the technical field of biology, in particular to broadleaf holly leaves, application of extracts of the broadleaf holly leaves and products for preventing or treating hypertension. The product has the following effects: the abundance of staphylococcus aureus (SA) in intestinal tracts is reduced or/and flora components are regulated; reducing the level in vivo of at least one exotoxin secreted by the SA; the expression of at least one of glutathione S-transferase and glutathione S-transferase P1 in paraventricular nucleus of hypothalamus is up-regulated. The invention also provides an application of the GSTM2/GSTP1 as a target spot in products for preventing or treating hypertension. The invention is further applied to prevention and treatment of hypertension by applying a product for up-regulating hypothalamic para-ventricular nucleus (PVN) antioxidant defense (GSTM2/GSTP1) through intestinal SA-exotoxin thereof. The invention provides a novel interventional antihypertensive target which is used for preparing novel drugs and other products for preventing and treating hypertension.
Resumen de: CN122351428A
The invention relates to medical application of HSPB6 in prevention and treatment of vascular calcification, and belongs to the technical field of biological medicine. It is confirmed for the first time that the expression level of HSPB6 is in significant negative correlation with the vascular calcification process, HSPB6 overexpression can significantly inhibit vascular smooth muscle cell osteogenesis phenotypic transformation, in-vivo and in-vitro vascular calcium salt deposition is reduced, and occurrence and development of vascular calcification are delayed. On the basis, the invention provides application of an HSPB6 expression level detection reagent in preparation of vascular calcification auxiliary diagnosis products and application of an HSPB6 specific overexpression reagent in preparation of drugs for preventing and/or treating vascular calcification, and a new target and scheme are provided for early diagnosis and targeted prevention and treatment of vascular calcification.
Resumen de: CN122357717A
The invention provides a collateral circulation biomarker MIA3 of a CTO patient and application of the collateral circulation biomarker MIA3, and belongs to the technical field of biology. The invention discloses and verifies that the plasma MIA3 level is remarkably positively correlated with the collateral circulation formation quality of a CTO patient, and the good collateral circulation prediction efficiency of the blood plasma MIA3 level is superior to that of a known vascular growth key factor VEGFA (Vascular Endothelial Growth Factor A). The MIA3 can serve as a high-value minimally invasive molecular marker and is used for noninvasively recognizing collateral circulation of a patient in the early stage before an interventional operation to form potential, so that risk stratification is carried out on the patient, and an objective basis is provided for making an individualized treatment decision (such as whether more positive intervention is needed or not). According to the application disclosed by the invention, the fact that MIA3 is a key link for regulating and controlling the collateral angiogenesis is clear, the activity of MIA3 is regulated up in a targeted manner, the collateral angiogenesis and maturation of an ischemic region can be accurately promoted, and a brand new non-drug and non-surgical treatment strategy is provided for CTO patients.
Resumen de: CN122351473A
The invention discloses application of SFRP3 in prevention and treatment of dilated cardiomyopathy, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the expression of SFRP3 in myocardial cells is reduced by means of gene interference, an RNA interference technology, an antibody or a small-molecule inhibitor and the like to treat dilated cardiomyopathy, so that the aims of improving cardiac functions, relieving cardiac dilation, improving myocardial fibrosis and effectively promoting myocardial repair are fulfilled; and a more effective treatment means with low side effect is provided for the treatment of dilated cardiomyopathy. The treatment thought provided by the invention not only can relieve the symptoms of the dilated cardiomyopathy, but also can regulate the physiological process of heart cells at the molecular level, and a new thought is provided for clinical treatment of the dilated cardiomyopathy.
Nº publicación: CN122357712A 10/07/2026
Solicitante:
JILIN UNIV
\u5409\u6797\u5927\u5B66
Resumen de: CN122357712A
The invention provides application of an ApoL1 gene as an acute myocardial infarction diagnosis marker, and belongs to the field of gene functions and application. By detecting the expression level of APOL1 protein and mRNA in peripheral blood of an acute myocardial infarction (AMI) group and a healthy population group, it is found that the expression level of the APOL1 protein in the AMI group is 1.41 times that of the healthy population group, and the mRNA level of the APOL1 in the AMI group is 1.25 times that of the healthy population group. Compared with healthy people, the mRNA and protein levels of APOL1 in bodies of AMI patients are remarkably improved, and high expression of APOL1 is proved to be an independent risk factor of AMI and can be used as one of biomarkers for predicting AMI.
BOPI
Sede Electrónica
